Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study
Qian Chen, Ian Campbell, Mark Elwood, Alana Cavadino, Phyu Sin Aye, Sandar Tin Tin · 2026
Read Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study by Qian Chen, Ian Campbell, Mark Elwood, Alana Cavadino, Phyu Sin Aye, Sandar Tin Tin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13538164.txt.
Description
Chen and five co-authors studied hormone testing in early breast disease in this paper from twenty twenty-six. Ductal carcinoma in situ is a non-invasive breast lesion. Hormone therapy after surgery may cut later cancer events, but use varies widely. The team linked a national breast register with drug records for over five thousand New Zealand women.
Only about fifteen percent ever had the estrogen receptor test that guides therapy. Testing peaked mid-period, then fell back. One region, Waikato, did most of the testing, tied to trial activity there. Of women with hormone-positive lesions, just a quarter started therapy. Their later event risk looked lowest, though not firmly so. The authors back standardized testing across regions.
Catalog record
| CREATOR | Qian Chen, Ian Campbell, Mark Elwood, Alana Cavadino, Phyu Sin Aye, Sandar Tin Tin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |